foxo4 dri peptide senolytic 2023 study

foxo4 dri peptide senolytic 2023 study Buy FOXO4-DRI 10mg | EU Tested FOXO4-DRI: Human Trial Status, Cancer

Name: foxo4 dri peptide senolytic 2023 study Buy FOXO4-DRI 10mg | EU Tested FOXO4-DRI: Human Trial Status, Cancer
Brand: creatorsinfotech.com
SKU: 38704233433
Price: 20.94 USD
Availability: InStock
Rating: 4.8451 (24 reviews)

FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data foxo4 dri peptide senolytic 2023 study Molecular modelling of the FOXO4 TP53 interaction to design peptides for the elimination of senescent cancer cells FOXO4 DRI induces keloid senescent fibroblast Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology

SKU: 38704233433 · From creatorsinfotech.com

4.8

USD20.94 USD66.94

Pay in 4 interest-free payments of $5.24 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Oct 26 - Oct 31

Description

Hypoxia-inducible lipid droplet-associated (HILPDA) is a novel peroxisome proliferator-activated receptor (PPAR) target involved in hepatic triglyceride secretion